Difference between revisions of "Part:BBa K404129"
VolkerMorath (Talk | contribs) |
|||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K404129 short</partinfo> | <partinfo>BBa_K404129 short</partinfo> | ||
+ | <br/><br><br> | ||
+ | {| style="color:black" cellpadding="6" cellspacing="1" border="2" align="right" | ||
+ | ! colspan="2" style="background:#66bbff;"|[https://parts.igem.org/Part:BBa_K404129 [AAV2]-left-ITR_phTERT_betaglobin_mCherry_hGH_[AAV2]-right-ITR ] | ||
+ | |- | ||
+ | ! colspan="2"|[[Image:Freiburg10_Vectorplasmid composite 11.png|300px]] | ||
+ | |- | ||
+ | |'''BioBrick Nr.''' | ||
+ | |[https://parts.igem.org/Part:BBa_K404129 BBa_K404129] | ||
+ | |- | ||
+ | |'''RFC standard''' | ||
+ | |[https://parts.igem.org/Help:Assembly_standard_10 RFC 10]<br/> | ||
+ | |- | ||
+ | |'''Requirement''' | ||
+ | |pSB1C3<br> | ||
+ | |- | ||
+ | |'''Source''' | ||
+ | |pAAV_MCS: provided by Stratagene<br/> | ||
+ | [https://parts.igem.org/Part:BBa_J06504 BBa_J06504] | ||
+ | |- | ||
+ | |'''Submitted by''' | ||
+ | |[http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] | ||
+ | |} | ||
+ | <br> | ||
+ | |||
+ | [[Image:Freiburg10_Vectorplasmid composite 11.png|left|thumb|400px]]<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br> | ||
+ | <html> | ||
+ | <head> | ||
+ | <meta http-equiv="Content-Type" | ||
+ | content="text/html; charset=windows-1252"> | ||
+ | <meta name="Generator" | ||
+ | content="Microsoft Word 14 (filtered)"> | ||
+ | <style> | ||
+ | <!-- | ||
+ | /* Font Definitions */ | ||
+ | @font-face | ||
+ | {font-family:Calibri; | ||
+ | panose-1:2 15 5 2 2 2 4 3 2 4;} | ||
+ | /* Style Definitions */ | ||
+ | p.MsoNormal, li.MsoNormal, div.MsoNormal | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:0cm; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:0cm; | ||
+ | margin-left:36.0pt; | ||
+ | margin-bottom:.0001pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast | ||
+ | {margin-top:0cm; | ||
+ | margin-right:0cm; | ||
+ | margin-bottom:10.0pt; | ||
+ | margin-left:36.0pt; | ||
+ | line-height:115%; | ||
+ | font-size:11.0pt; | ||
+ | font-family:"Calibri","sans-serif";} | ||
+ | .MsoChpDefault | ||
+ | {font-family:"Calibri","sans-serif";} | ||
+ | .MsoPapDefault | ||
+ | {margin-bottom:10.0pt; | ||
+ | line-height:115%;} | ||
+ | @page WordSection1 | ||
+ | {size:612.0pt 792.0pt; | ||
+ | margin:70.85pt 70.85pt 2.0cm 70.85pt;} | ||
+ | div.WordSection1 | ||
+ | {page:WordSection1;} | ||
+ | --> | ||
+ | </style> | ||
+ | </head> | ||
+ | <body lang="EN-US"> | ||
+ | <div class="WordSection1"> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Producing | ||
+ | recombinant virus particles for therapeutical | ||
+ | applications is, besides specific cell targeting, purification and | ||
+ | quantification assays of AAV-2, one intention of the Virus Construction | ||
+ | Kit | ||
+ | provided by the iGEM team Freiburg_Bioware 2010. For obtaining a | ||
+ | modular | ||
+ | toolkit, the complex biological system of the Adeno-associated virus | ||
+ | serotype 2 | ||
+ | was examined by an exhaustive literature search. Subsequently, the | ||
+ | essential | ||
+ | components for AAV-2 particle production were extracted and redesigned | ||
+ | to match | ||
+ | the iGEM standard.</span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">The provided | ||
+ | tripartite system is independent of a | ||
+ | superinfection of Adeno- or herpes simplex viruses since the | ||
+ | genes encoding | ||
+ | the required helper-proteins are co-transfected. Inside the eukaryotic | ||
+ | host | ||
+ | cell, the DNA sequence containing the inverted terminal repeats (ITRs) | ||
+ | is | ||
+ | extracted and later encapsidated into the preformed capsids after | ||
+ | production of | ||
+ | single-stranded DNA. Consequently, this plasmid is known as the vector | ||
+ | plasmid | ||
+ | (pGOI). Promoter, <i>beta-globin</i> intron and the hGH | ||
+ | terminator signal are | ||
+ | flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate | ||
+ | transgene | ||
+ | expression. The vector plasmid containing the desired gene of interest | ||
+ | is | ||
+ | cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or | ||
+ | BBa_K404003) | ||
+ | and the pHelper plasmid. To obtain the fully assembled vector plasmid, | ||
+ | several | ||
+ | assembly steps have to be performed. </span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">The Composite | ||
+ | part </span><span style="font-size: 10pt; line-height: 115%;">[AAV2]-left-ITR_pCMV_betaglobin_mCherry_hGH_[AAV2]-right-ITR | ||
+ | provided by the iGEM team Freiburg_Bioware comprises all <i>cis</i>-elements | ||
+ | required for efficient transgene expression in mammalian cells | ||
+ | (polyadenylation | ||
+ | terminator: </span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404108 </span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">and | ||
+ | transcription enhancer element: </span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">BBa_K404107)</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;"> and | ||
+ | encapsidation into virus | ||
+ | particles (</span><span | ||
+ | style="font-size: 10pt; line-height: 115%;">ITRs: | ||
+ | BBa_K404100 and BBa_K404101). The mCherry coding sequence as gene of | ||
+ | interest | ||
+ | enables facile detection of transduced cells using flow cytometry or | ||
+ | fluorescence microscopy.</span></p> | ||
+ | <p class="MsoNormal" style="text-align: justify;"><span | ||
+ | style="font-size: 10pt; line-height: 115%;">Furthermore, </span>by | ||
+ | providing the tumor-specific promoter | ||
+ | with the “Virus Vonstruction Kit”, the iGEM Freiburg_Bioware team 2010 | ||
+ | ensures | ||
+ | another layer of specificity and safety to the recombinant viral vector | ||
+ | system. | ||
+ | Telomerase activation is a critical step in human tumorigenesis and | ||
+ | about | ||
+ | 90% of human tumors show telomerase activity. In most somatic | ||
+ | cells, | ||
+ | the phTERT promoter is inactive. This prevents expression of the hTERT | ||
+ | protein | ||
+ | subunit and renders the healthy tissue telomerase negative. </p> | ||
+ | <p class="MsoNormal"> </p> | ||
+ | </div> | ||
+ | </body> | ||
+ | </html> | ||
− | |||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here |
Latest revision as of 14:27, 1 November 2010
[AAV2]-left-ITR_phTERT_betaglobin_mCherry_hGH_[AAV2]-right-ITR
[AAV2-left-ITR_phTERT_betaglobin_mCherry_hGH_[AAV2]-right-ITR ] | |
---|---|
BioBrick Nr. | BBa_K404129 |
RFC standard | RFC 10 |
Requirement | pSB1C3 |
Source | pAAV_MCS: provided by Stratagene |
Submitted by | [http://2010.igem.org/Team:Freiburg_Bioware FreiGEM 2010] |
Producing recombinant virus particles for therapeutical applications is, besides specific cell targeting, purification and quantification assays of AAV-2, one intention of the Virus Construction Kit provided by the iGEM team Freiburg_Bioware 2010. For obtaining a modular toolkit, the complex biological system of the Adeno-associated virus serotype 2 was examined by an exhaustive literature search. Subsequently, the essential components for AAV-2 particle production were extracted and redesigned to match the iGEM standard.
The provided tripartite system is independent of a superinfection of Adeno- or herpes simplex viruses since the genes encoding the required helper-proteins are co-transfected. Inside the eukaryotic host cell, the DNA sequence containing the inverted terminal repeats (ITRs) is extracted and later encapsidated into the preformed capsids after production of single-stranded DNA. Consequently, this plasmid is known as the vector plasmid (pGOI). Promoter, beta-globin intron and the hGH terminator signal are flanked by the ITRs (ITRs, BBa_K404100 and BBa_K404101) and regulate transgene expression. The vector plasmid containing the desired gene of interest is cotransfected with the RepCap plasmid (BBa_K404001, BBa_K404002 or BBa_K404003) and the pHelper plasmid. To obtain the fully assembled vector plasmid, several assembly steps have to be performed.
The Composite part [AAV2]-left-ITR_pCMV_betaglobin_mCherry_hGH_[AAV2]-right-ITR provided by the iGEM team Freiburg_Bioware comprises all cis-elements required for efficient transgene expression in mammalian cells (polyadenylation terminator: BBa_K404108 and transcription enhancer element: BBa_K404107) and encapsidation into virus particles (ITRs: BBa_K404100 and BBa_K404101). The mCherry coding sequence as gene of interest enables facile detection of transduced cells using flow cytometry or fluorescence microscopy.
Furthermore, by providing the tumor-specific promoter with the “Virus Vonstruction Kit”, the iGEM Freiburg_Bioware team 2010 ensures another layer of specificity and safety to the recombinant viral vector system. Telomerase activation is a critical step in human tumorigenesis and about 90% of human tumors show telomerase activity. In most somatic cells, the phTERT promoter is inactive. This prevents expression of the hTERT protein subunit and renders the healthy tissue telomerase negative.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 2383